Die Einträge von „Technologien aus Wien“ sind in der Projektsprache abgebildet.
Technologien aus Wien
Antibody-based therapeutics for the prevention and treatment of tuberculosis and other important infectious diseases.Austrianni GmbH is a start-up biotechnology company with the founding goal of developing novel biological therapeutics for the treatment of infectious diseases that are of major global importance. Tuberculosis is its exclusive initial focus. The biological therapies the company is developing are antibodies, and it is significantly enabled in accomplishing this through access to a powerful discovery platform customized for the isolation of therapeutic monoclonal antibodies.
Novel Antibody-Based ImmunotherapyImmunotherapy is a form of therapy in which a patient’s immune system is changed in some way such that a beneficial type of immune response is generated. It has recently risen to prominence in the treatment of cancer and is the subject of a large amount of ongoing biotechnology and pharmaceutical research. The goal of this project is to develop a novel form of immunotherapy involving changes in lipid metabolism in cells of the immune system. Using a state-of-the-art discovery platform, biological therapeutics (antibodies) will be isolated that target a specific enzyme found on the surfaces of certain kinds of leukocytes. Antibodies that inhibit the catalytic function of the enzyme will then be evaluated for therapeutic efficacy using customized preclinical testing systems. The project is expected to yield a novel class of biological immunotherapeutic agent that may have value in treating a range of disease conditions including those of an oncological or infectious nature.
Kontakt Wirtschaftsagentur Wien
Die Informations- und Vernetzungsangebote werden im Rahmen des Projektes „IC3 Innovation by Co-Operation, Co-Creation and Community Building“ aus Mitteln des Europäischen Fonds für regionale Entwicklung kofinanziert. Nähere Informationen zum IWB/EFRE-Förderprogramm